Alpha Cognition Inc
XTSX:ACOG
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Alpha Cognition Inc
Accrued Liabilities
Alpha Cognition Inc
Accrued Liabilities Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Accrued Liabilities | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
A
|
Alpha Cognition Inc
XTSX:ACOG
|
Accrued Liabilities
$829.3k
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
B
|
Bright Minds Biosciences Inc
CNSX:DRUG
|
Accrued Liabilities
CA$540.6k
|
CAGR 3-Years
134%
|
CAGR 5-Years
112%
|
CAGR 10-Years
N/A
|
|
|
Aurinia Pharmaceuticals Inc
NASDAQ:AUPH
|
Accrued Liabilities
$65.7m
|
CAGR 3-Years
32%
|
CAGR 5-Years
141%
|
CAGR 10-Years
48%
|
|
|
X
|
Xenon Pharmaceuticals Inc
NASDAQ:XENE
|
Accrued Liabilities
$37.9m
|
CAGR 3-Years
40%
|
CAGR 5-Years
36%
|
CAGR 10-Years
38%
|
|
|
Eupraxia Pharmaceuticals Inc
TSX:EPRX
|
Accrued Liabilities
CA$118.6k
|
CAGR 3-Years
81%
|
CAGR 5-Years
-6%
|
CAGR 10-Years
N/A
|
|
|
e
|
enGene Holdings Inc
NASDAQ:ENGN
|
Accrued Liabilities
$16.7m
|
CAGR 3-Years
75%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Alpha Cognition Inc
Glance View
Alpha Cognition, Inc. is a clinical stage biopharmaceutical company that develops treatments for underserved neurodegenerative diseases such as Alzheimer's Dementia and Amyotrophic Lateral Sclerosis (ALS). The company is headquartered in Vancouver, British Columbia. The company went IPO on 2018-09-19. The Company’s therapeutic pipeline includes ALPHA-1062 and ALPHA-0602. The Company’s ALPHA-1062 development program is primarily focused on clinical and regulatory development, chemistry, manufacturing and control development, and commercial readiness. ALPHA-0602 is a gene therapy program delivering progranulin, a neurotrophic protein, and is in preclinical development for the treatment of amyotrophic lateral sclerosis. The company has three development programs: ALPHA-1062 in combination with memantine for the treatment of moderate-to-severe Alzheimer’s; ALPHA-1062 nasal formulation for the treatment of mild traumatic brain injury, and ALPHA-0602, for the treatment of amyotrophic lateral sclerosis. ALPHA-1062 is also being researched as a treatment for mild-traumatic brain injury.
See Also
What is Alpha Cognition Inc's Accrued Liabilities?
Accrued Liabilities
271.9k
USD
Based on the financial report for Dec 31, 2021, Alpha Cognition Inc's Accrued Liabilities amounts to 271.9k USD.
What is Alpha Cognition Inc's Accrued Liabilities growth rate?
Accrued Liabilities CAGR 1Y
54%
Over the last year, the Accrued Liabilities growth was 54%.
